河南医学研究2024,Vol.33Issue(4) :720-723.DOI:10.3969/j.issn.1004-437X.2024.04.034

XELOX方案新辅助化疗治疗进展期胃癌的效果

Curative Effect of Neoadjuvant Chemotherapy with XELOX Regimen on Advanced Gastric Cancer

余武林 周斌 张小龙 崔广军
河南医学研究2024,Vol.33Issue(4) :720-723.DOI:10.3969/j.issn.1004-437X.2024.04.034

XELOX方案新辅助化疗治疗进展期胃癌的效果

Curative Effect of Neoadjuvant Chemotherapy with XELOX Regimen on Advanced Gastric Cancer

余武林 1周斌 1张小龙 1崔广军1
扫码查看

作者信息

  • 1. 信阳市人民医院普通外科,河南信阳 464000
  • 折叠

摘要

目的 观察XELOX方案(奥沙利铂+卡培他滨)新辅助化疗治疗进展期胃癌的效果及其对血清恶性肿瘤相关物质群(TSGF)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、胃蛋白酶原(PG)水平的影响.方法 选取医院80例进展期胃癌患者,均行XELOX化疗,比较治疗前后血清TSGF、CEA、CA19-9及PG[PG Ⅰ、PGⅡ、PG Ⅰ/PGⅡ值(PGR)],并观察患者疗效与不良反应情况.结果 化疗第2疗程总有效率(38.75%)高于化疗第1疗程(23.75%)(P<0.05);患者化疗第1疗程与第2疗程血清TSGF、CEA、CA19-9水平较治疗前降低(P<0.05),且化疗第2疗程低于化疗第1疗程(P<0.05);化疗第1疗程,患者PG Ⅰ、PGR较治疗前升高(P<0.05);化疗第2疗程,患者PG Ⅰ、PGR较第1疗程升高(P<0.05),PGⅡ低于治疗前与化疗第1疗程(P<0.05);患者白细胞降低Ⅰ级(31.25%)、恶心呕吐Ⅰ级(33.75%)、神经毒性Ⅰ级(35.00%)、手足综合征Ⅰ级(31.25%)发生率较高,Ⅲ级不良反应发生率较低,无Ⅳ级不良反应.结论 随着XELOX方案新辅助化疗的进行,进展期胃癌临床疗效升高,其可有效降低TSGF、CEA、CA19-9水平,并提高PGI水平,安全性与患者耐受性良好.

Abstract

Objective To observe the curative effect of neoadjuvant chemotherapy with XELOX regimen(oxaliplatin and capecitabine)on advanced gastric cancer and its influences on levels of serum tumor supplied group of factors(TSGF),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and pepsinogen(PG).Methods A total of 80 patients with advanced gastric cancer in the hospital were enrolled.All underwent XELOX chemotherapy.Serum TSGF,CEA,CA19-9 and PG[PG Ⅰ,PG Ⅱ,PG Ⅰ to PG Ⅱ ratio(PGR)]before and after treatment were compared.The curative effect and adverse reactions were observed.Results The total response rate in the second course of chemotherapy(38.75%)was higher than that in the first course of chemotherapy(23.75%)(P<0.05).In the first and second course of chemotherapy,the levels of serum TSGF,CEA and CA19-9 were lower than those before treatment(P<0.05).The above indexes in the second course of chemotherapy were lower than those in the first course of chemotherapy(P<0.05).In the first course of chemotherapy,PG Ⅰ and PGR were higher than those before treatment(P<0.05).In the second course of chemotherapy,PG Ⅰ and PGR were higher than those in the first course of chemotherapy(P<0.05).PG Ⅱ was lower than that before treatment and in the first course of chemotherapy(P<0.05).The incidence of leukopenia reduction at grade Ⅰ(31.25%),nausea and vomiting at grade Ⅰ(33.75%),neurotoxicity at grade Ⅰ(35.00%)and hand-foot syndrome at grade Ⅰ(31.25%)was relatively higher,while incidence of adverse reactions at grade Ⅲ was relatively lower.There was no adverse reactions at grade Ⅳ.Conclusion With process of neoadjuvant chemotherapy with XELOX regimen,clinical curative effect of advanced gastric cancer is increased,which can effectively reduce levels of TSGF,CEA,CA19-9,and increase the level of PGI.The safety and patients tolerance are good.

关键词

XELOX方案/新辅助化疗/进展期胃癌/疗效

Key words

XELOX regimen/neoadjuvant chemotherapy/advanced gastric cancer/curative effect

引用本文复制引用

出版年

2024
河南医学研究
河南省医学科学院

河南医学研究

影响因子:0.979
ISSN:1004-437X
参考文献量16
段落导航相关论文